YaoGeJu

Company directoryChina company filings

Newland PharmaceuticalCo.,Ltd.

As of 18 November 2026, for the company name Newland PharmaceuticalCo.,Ltd. as recorded, the chemical-drug catalogue lists 2 active records with this name as holder; 19 active API registrations list this name as first registered company.

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference

CDE data as of
2026/11/18
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.

Drug filings

9 acceptance records as first applicant, grouped into 5 source drug names. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Oseltamivir Phosphate Capsules 3 records · Latest accepted 2026/10/28

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2602633Generic2026/10/28Newland PharmaceuticalCo.,Ltd.; Shandong Yao Shi Pharma Co., Ltd. romanizedCDE ↗
CYHS2602632Generic2026/10/28Newland PharmaceuticalCo.,Ltd.; Shandong Yao Shi Pharma Co., Ltd. romanizedCDE ↗
CYHS2602631Generic2026/10/28Newland PharmaceuticalCo.,Ltd.; Shandong Yao Shi Pharma Co., Ltd. romanizedCDE ↗
Ruxolitinib Phosphate Tablets 3 records · Latest accepted 2026/10/19

Generic · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2602561Generic2026/10/19Newland PharmaceuticalCo.,Ltd.; Shandong Yao Shi Pharma Co., Ltd. romanizedCDE ↗
CYHS2602560Generic2026/10/19Newland PharmaceuticalCo.,Ltd.; Shandong Yao Shi Pharma Co., Ltd. romanizedCDE ↗
CYHS2602559Generic2026/10/19Newland PharmaceuticalCo.,Ltd.; Shandong Yao Shi Pharma Co., Ltd. romanizedCDE ↗
Moxifloxacin Hydrochloride And Sodium Chloride Injection 1 records · Latest accepted 2025/08/01

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2502766Generic2025/08/01Newland PharmaceuticalCo.,Ltd.; Shandong Hua Lu Pharmaceutical Co., Ltd. romanizedCDE ↗
Moxifloxacin Hydrochloride Tablets 1 records · Latest accepted 2024/09/12

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2403049Generic2024/09/12Newland PharmaceuticalCo.,Ltd.; Xu Chang Wei Lai Pharmaceutical Co., Ltd. romanizedCDE ↗
Vildagliptin Tablets 1 records · Latest accepted 2024/03/04

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2400749Generic2024/03/04Newland PharmaceuticalCo.,Ltd.; NORTH CHINA PHARMACEUTICAL COMPANY.LTDCDE ↗

Changes in the last 90 days

6 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Accepted: 6 applications

  1. 2026/10/28Accepted

    Oseltamivir Phosphate Capsules

    CYHS2602633

    Fact date: 2026/10/28 · Date added to this site: 2026/10/29

    View source ↗
  2. 2026/10/28Accepted

    Oseltamivir Phosphate Capsules

    CYHS2602632

    Fact date: 2026/10/28 · Date added to this site: 2026/10/29

    View source ↗
  3. 2026/10/28Accepted

    Oseltamivir Phosphate Capsules

    CYHS2602631

    Fact date: 2026/10/28 · Date added to this site: 2026/10/29

    View source ↗
  4. 2026/10/19Accepted

    Ruxolitinib Phosphate Tablets

    CYHS2602561

    Fact date: 2026/10/19 · Date added to this site: 2026/10/22

    View source ↗
  5. 2026/10/19Accepted

    Ruxolitinib Phosphate Tablets

    CYHS2602560

    Fact date: 2026/10/19 · Date added to this site: 2026/10/22

    View source ↗
  6. 2026/10/19Accepted

    Ruxolitinib Phosphate Tablets

    CYHS2602559

    Fact date: 2026/10/19 · Date added to this site: 2026/10/22

    View source ↗

Under review

6 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Oseltamivir Phosphate Capsules CYHS2602633Generic2026/10/28Newland PharmaceuticalCo.,Ltd.; Shandong Yao Shi Pharma Co., Ltd. romanizedCDE ↗
Oseltamivir Phosphate Capsules CYHS2602632Generic2026/10/28Newland PharmaceuticalCo.,Ltd.; Shandong Yao Shi Pharma Co., Ltd. romanizedCDE ↗
Oseltamivir Phosphate Capsules CYHS2602631Generic2026/10/28Newland PharmaceuticalCo.,Ltd.; Shandong Yao Shi Pharma Co., Ltd. romanizedCDE ↗
Ruxolitinib Phosphate Tablets CYHS2602561Generic2026/10/19Newland PharmaceuticalCo.,Ltd.; Shandong Yao Shi Pharma Co., Ltd. romanizedCDE ↗
Ruxolitinib Phosphate Tablets CYHS2602560Generic2026/10/19Newland PharmaceuticalCo.,Ltd.; Shandong Yao Shi Pharma Co., Ltd. romanizedCDE ↗
Ruxolitinib Phosphate Tablets CYHS2602559Generic2026/10/19Newland PharmaceuticalCo.,Ltd.; Shandong Yao Shi Pharma Co., Ltd. romanizedCDE ↗

Catalogue holder records

2 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Moxifloxacin Hydrochloride TabletsNewland PharmaceuticalCo.,Ltd.Xu Chang Wei Lai Pharmaceutical Co., Ltd. romanized国药准字H202643032026/05/12Generic approved under the new chemical-drug registration classificationCDE ↗
Vildagliptin TabletsNewland PharmaceuticalCo.,Ltd.NORTH CHINA PHARMACEUTICAL COMPANY.LTD国药准字H202549482025/07/22Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

19 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.

NameCompany / applicantRegistration numberStatusSource update dateView source
磷酸奥司他韦 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20250001153I2025/11/07CDE ↗
艾普拉唑 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20250001026I2025/09/28CDE ↗
磷酸芦可替尼 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20250000430I2025/05/16CDE ↗
苯磺酸左氨氯地平 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20240001547A2026/07/07CDE ↗
苯磺酸氨氯地平 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20240001499A2026/07/25CDE ↗
磺达肝癸钠 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20240001407A2026/09/29CDE ↗
富马酸亚铁 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20240000827A2026/02/27CDE ↗
硫酸氢氯吡格雷 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20230001350A2026/07/07CDE ↗
艾司奥美拉唑钠 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20230001270A2026/07/01CDE ↗
马来酸氯苯那敏 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20230000860A2026/02/27CDE ↗
依托咪酯 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20230000902A2025/08/28CDE ↗
他达拉非 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20220001272A2025/08/28CDE ↗
盐酸罗哌卡因 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20220001314A2026/01/28CDE ↗
艾司奥美拉唑镁 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20220000624A2025/04/11CDE ↗
利多卡因 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20210001153A2024/09/11CDE ↗
盐酸莫西沙星 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20210000980A2026/02/27CDE ↗
维格列汀 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20200001467A2025/08/28CDE ↗
盐酸萘甲唑啉 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20200000956A2026/08/17CDE ↗
盐酸利多卡因 · No verified English nameNewland PharmaceuticalCo.,Ltd.Y20200000297A2026/07/17CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/18 · Current coverage may be incomplete
Chemical-drug catalogue
Last successful update: 2026/11/18
API registrations
Last successful update: 2026/11/18
NMPA drug delivery notices
Last successful update: 2026/11/19

Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.